Fluorescently Labeled Morphine Derivatives for Bioimaging Studies.
Raymond LamArisbel B GondinMeritxell CanalsBarrie KellamStephen J BriddonBim GrahamPeter J ScammellsPublished in: Journal of medicinal chemistry (2018)
Opioids, like morphine, are the mainstay analgesics for the treatment and control of pain. Despite this, they often exhibit severe side effects that limit dose; patients often become tolerant and dependent on these drugs, which remains a major health concern. The analgesic actions of opioids are primarily mediated via the μ-opioid receptor, a member of the G protein-coupled receptor superfamily. Thus far, development of small molecule fluorescent ligands for this receptor has resulted in antagonists, somewhat limiting the use of these probes. Herein, we describe our work on the development of a small molecule fluorescent probe based on the clinically used opiate morphine and initial characterization of its behavior in cell-based assays.
Keyphrases
- small molecule
- living cells
- fluorescent probe
- chronic pain
- pain management
- protein protein
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- quantum dots
- neuropathic pain
- single molecule
- public health
- single cell
- prognostic factors
- pet imaging
- stem cells
- computed tomography
- early onset
- binding protein
- spinal cord injury
- patient reported outcomes
- climate change
- pet ct
- human health